# Telavancin (Vibativ)

> Lipoglycopeptide for complicated skin infections and HABP/VABP.

Source: https://peptides.cafe/peptide/telavancin
Category: Lipoglycopeptide · Antibiotic
Tag: FDA-Approved · Antibiotic

## Mechanism
Semisynthetic vancomycin derivative with a lipophilic side chain that inhibits peptidoglycan synthesis and depolarizes the bacterial cell membrane, active against MRSA and other Gram-positives.

## Research areas
- Complicated skin and skin structure infections
- Hospital-acquired and ventilator-associated bacterial pneumonia caused by S. aureus

## Common research protocols
- Daily IV: 10 mg/kg IV every 24 hours.

## Study summaries
- "ATLAS and ATTAIN trials" — CID (2008–2011): Non-inferior to vancomycin in cSSSI and HABP/VABP.

## Considerations
- FDA-approved.
- Boxed warning: nephrotoxicity, increased mortality in pre-existing moderate/severe renal impairment HAP.
- Avoid in pregnancy.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.